News

Esteemed Researcher and Clinical Oncologist W. Michael Korn, M.D. Joins Caris Life Sciences as Chief Medical Officer

Executive Appointment Further Strengthens the Company’s Position as a Precision Medicine Leader Translating Molecular Insights into Therapeutic Action IRVING, Texas, September 19, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the appointment of W. Michael Korn, M.D., as its Chief Medical Officer. … Continued

Caris Life Sciences Announces Presentations at ESMO 2017 Highlighting Ability of its Tumor Molecular Profiling to Develop Therapeutic Strategies

Comprehensive Genomic Profiling Plus of DNA, RNA and Proteins Enables Personalized Therapy Decisions across Immunotherapy, Targeted Therapy and Chemotherapy IRVING, Texas, Sept. 7, 2017 – Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced results from two studies that further validate the benefits of its … Continued

Caris Life Sciences Selected to Perform Genomic Profiling for UC-GENOME Study

IRVING, Texas, Aug. 30, 2017 – The Bladder Cancer Genomics Consortium (BCGC) and Hoosier Cancer Research Network today announced the selection of Caris Life Sciences® to perform genomic profiling for UC-GENOME, a large-scale genomically driven bladder cancer study. The study, also known as HCRN GU15-217, is the first project of the BCGC, a collaborative effort … Continued

Caris Life Sciences’ Molecular Intelligence Platform Identifies Patients with MSI-High (or Mismatch Repair Deficient) Solid Tumors More Likely to Respond to Immunotherapy

Results Published in Science Demonstrate Molecular Profile of Tumor Cells Rather than Tumor Origin Can Drive Therapeutic Strategy IRVING, Texas, June 8, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today highlighted an article published in Science containing data on microsatellite instability (MSI) status … Continued

Caris Life Sciences’ Molecular Intelligence Reports Optimized for the American Society of Clinical Oncology, Inc. TAPUR Study

Caris Molecular Intelligence Tumor Profiling Reports Optimized to Molecularly Identify Genomic Alterations for the TAPUR Study IRVING, Texas, June 8, 2017 – Caris Life Sciences®, a leading innovator in molecular science, and the American Society of Clinical Oncology, Inc. (ASCO®), announced that Caris is one of the first laboratories to have a test report optimized … Continued

Caris Life Sciences, National Cancer Institute and ECOG-ACRIN Collaborate to Molecularly Identify Candidates for the NCI-MATCH Clinical Trial

Caris to Participate in Next-Generation Sequencing Concordance Evaluation with NCI-MATCH Trial Laboratory Network IRVING, Texas, June 7, 2017 – Caris Life Sciences®, a leading innovator in molecular science, today announced a collaboration with the National Cancer Institute (NCI) for the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial, which is being implemented … Continued

Caris Life Sciences’ Molecular Intelligence Platform Measures Prevalence of Oncogenic Homologous Recombination Pathway Mutations across 53,000 Tumors

Results have Wide Applicability for Personalized Medicine and Drug Discovery and Development Data presented in Oral Abstract Session at the 2017 ASCO Annual Meeting IRVING, Tex., June 5, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced results of a molecular profiling analysis … Continued

Caris Life Sciences to Present Key Research Findings on its Molecular Intelligence Platform at the 2017 ASCO Annual Meeting

Presentations Demonstrate Utility of Tumor Profiling to Guide Individualized Treatment IRVING, Tex., May 24, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the acceptance of 11 abstracts, including an oral abstract session, two poster discussion sessions and eight poster sessions, by the … Continued

Caris Life Sciences Appoints John Marshall, M.D., as Chief Medical Officer

IRVING, Texas, May 17, 2017 – Caris Life Sciences, a leading innovator in molecular science, today announced the appointment of John Marshall, M.D., as its Chief Medical Officer. Dr. Marshall will direct the company’s oncology research efforts via the Caris Research Institute™ and guide clinical strategies for innovative precision medicine tools and tumor profiling services, … Continued

1 2 3 15

About Our News

Search to find the latest new about Caris Molecular Intelligence®, sign up for news alerts, and be sure to follow us on social media.